KK2260 is a fully human tetravalent bispecific antibody targeting TfR1 and EGFR1,2
KK2260 is an EGFR driven, local-acting TfR1 degrader1
- TfR1 is highly expressed in different types of cancers as well as certain normal cells, such as erythroid lineage progenitor cells in the bone marrow, posing a risk of side effects, including severe anemia
- KK2260 is a bsAb with binding sites for TfR1 and EGFR, designed to target EGFR-expressing cells for selective anti-cancer activity
- TfR1 is a transmembrane glycoprotein involved in iron uptake and regulation of cell growth that has been identified as a target for cancer therapy
REGULGENTTM technology2
- REGULGENTTM is a novel symmetric bsAb, comprising 2 Fab domains, using a common light chain to simplify design and production, addressing challenges such as heterogeneity and aggregation associated with bsAb manufacturing
- KK2260 is an N-terminal type REGULGENTTM
Proprietary bispecific antibody technology.
bsAb, bispecific antibody; EGFR, epidermal growth factor receptor; Fab, fragment antigen-binding; TfR1, transferrin receptor 1.
References: 1. Mitamura K et al. Cancer Res. 2024;84(6 supp):1892. 2. Saito S et al. Protein Sci. 2024;33(10):e5121.